Focus: Cancer Center Featured Story 2

• share
• favorite_border

Moffitt Cancer Center researchers have developed a groundbreaking method for the scalable synthesis of withanolides.

• share
• favorite_border

Fred Hutch Cancer Center has launched (PS2@FH), a new summer research program that trains middle school and high school teachers in Fred Hutch labs to expand hands-on learning experiences they can take back to the classroom.

• share
• favorite_border

• 97% of HER2+, early-stage patients treated with trastuzumab emtansine (T-DM1) were free of cancer recurrence five years after treatment • Prognostic test (HER2DX) shown helpful in identifying patients at greatest risk for recurrence

• share
• favorite_border

Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support standard use of the more precise intensity-modulated radiotherapy (IMRT) over the alternative 3D-conformal radiotherapy (3D-CRT) for patients with unresectable, locally advanced non-small cell lung cancer (NSCLC).

• share
• favorite_border

MD Anderson and Rice announced the creation of the Cancer Bioengineering Collaborative to develop innovative technologies and bioengineering approaches to improve cancer research, diagnosis and treatment.

• share
• favorite_border

A new study led by researchers at Moffitt Cancer Center introduces an adaptive therapy approach that could optimize PARP inhibitor maintenance therapy, offering a more personalized and potentially less toxic treatment option for patients. Their work is featured as the cover article of the June 19 issue of Cell Systems.

• share
• favorite_border

NCCN shares new data on continued high prevalence for cancer drug shortages in the United States. In the latest survey, carboplatin and cisplatin shortages fell to 11% and 7% respectively, but 89% of centers surveyed continue to report shortages for at least one type of systemic therapy; 75% are experiencing two or more drug shortages.

• share
• favorite_border

These clinical trial results point to the first safe and effective use of immunotherapy for patients with microsatellite stable colorectal cancer, the most common subtype of the disease. The encouraging results of this phase I trial have prompted Dana-Farber investigators to move forward with a phase III trial of this immunotherapy combination.

• share
• favorite_border

In Greek mythology, a Chimera is a creature of change, a being possessing the forms of lion, goat and dragon. But unlike the mythical creature, a new approach to fighting cancer cells throughout the body is very real and has arrived at The University of New Mexico Comprehensive Cancer Center.

• share
• favorite_border

The FDA has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center. The supplemental designation applies to SurVaxM as treatment for not just adult glioblastoma but any malignant glioma in children or adults.

• share
• favorite_border

Research by Hemn Mohammadpour, DVM, PhD, and colleagues at Roswell Park Comprehensive Cancer Center offers new insights into tumor biology and may lay the groundwork for more effective cancer immunotherapy. Their preclinical findings were published today in the journal Cellular & Molecular Immunology.

• share
• favorite_border

Bolstered by $6.3 million raised in donations, the Rutgers Board of Governors today approved the establishment of the William Hait Endowed Directorship at Rutgers Cancer Institute. Moving forward, the director of Rutgers Cancer Institute will be known as the William Hait Director.

• share
• favorite_border

Patients with pancreatic cancer who received chemotherapy both before and after surgery experienced longer survival rates than would be expected from surgery followed by chemotherapy, according to a new study from researchers at Yale Cancer Center (YCC) and Yale School of Medicine. The study, published June 20 in JAMA Oncology, included patients with pancreatic ductal adenocarcinoma (PDAC), which accounts for 90% of pancreatic cancers.

• share
• favorite_border

Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity of the CAR NK cells, according to researchers from The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

• share
• favorite_border

An analysis of data from a randomized clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib, an anti-inflammatory drug, after surgery lived significantly longer and had longer disease-free survival compared to those without the mutation.

• share
• favorite_border

The Bristol-Myers Squibb Children’s Hospital (BMSCH) at Robert Wood Johnson University Hospital (RWJUH) and Rutgers Cancer Institute recently dedicated the new Pediatric Bone Marrow Transplantation and Cellular Therapy Program recognizing the many donors who supported the program.

• share
• favorite_border

New recommendations on the optimal use of radiation therapy for HPV-associated OPSCC are based on evidence from multiple clinical trials and aim to maintain good outcomes and reduce acute and late effects.

• share
• favorite_border

The Institute for Data Science in Oncology (IDSO) at The University of Texas MD Anderson Cancer Center today announced the establishment of its internal advisory council to identify needs and opportunities for data science development and integration across MD Anderson, advancing work that will yield significant benefits for patients and families.

• share
• favorite_border

Fred Hutch Cancer Center announced eight recipients of the national Dr. Eddie Méndez Scholar Award, which recognizes which recognizes outstanding early-career scientists from underrepresented backgrounds who are studying cancer, infectious diseases and basic sciences.

• share
• favorite_border

NCCN Guidelines for Patients earn Hermes Award for electronic media and Communicator Award for medical print content. NCCN Patient Webinars earn Digital Health Award and Viddy Award for outstanding achievement in video and digital production.

• share
• favorite_border

Immunotherapy, a type of cancer treatment that uses a person’s own immune system to attack cancer cells, is continuing to transform cancer treatment and care.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research, and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

• share
• favorite_border

The UNM Comprehensive Cancer Center is partnering with Northern Arizona University, New Mexico State University and the Burrell College of Osteopathic Medicine, which is located on NMSU’s campus in Las Cruces, to connect emerging cancer disparities researchers with mentors to continue developing these scholars.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center and Sibylla Biotech today announced a strategic collaboration agreement to discover and develop novel small-molecule cancer therapies known as folding interfering degraders (FIDs), which disrupt the proper folding of target proteins and lead to their degradation.

• share
• favorite_border

Researchers at Brigham and Women’s Hospital and Dana-Farber Cancer Institute found significant uptake and scalability in phone-based “PATH” intervention to improve psychological well-being in blood cancer patients, according to new study in JNCCN.

• share
• favorite_border

Leptomeningeal disease is a rare but lethal complication faced by late-stage melanoma patients. It occurs when cancer cells spread to the membranes covering the brain and spinal cord, or the leptomeninges. This condition, which affects 5% to 8% of melanoma patients, often leads to rapid deterioration and is notoriously resistant to therapies. However, a new Moffitt Cancer Center study, published today in Cell Reports Medicine, uncovers the mechanisms that drive this drug resistance, offering new avenues for potential treatments.

• share
• favorite_border

New study shows UC Davis total-body advanced PET scanner EXPLORER can visualize dual blood supply in lungs and effectively evaluate lung cancer and track treatment progress.

• share
• favorite_border

As many as 40% of preterm infants in the U.S. suffer from nephrocalcinosis, a condition that deposits excess calcium in kidneys.

• share
• favorite_border

Roswell Park Comprehensive Cancer Center has earned its most highly rated grant from the National Cancer Institute (NCI). The NCI renewed Roswell Park’s status as a Comprehensive Cancer Center - a designation held by less than 4% of cancer centers- awarding Roswell Park the highest possible “Exceptional” rating as it renewed a grant Roswell Park has successfully competed for since 1972.

• share
• favorite_border

Bioengineering is revolutionizing cancer research, and Moffitt Cancer Center is at the forefront of this transformative movement. Moffitt is the first National Cancer Institute-designated comprehensive cancer center with a dedicated bioengineering department. This area of science integrates engineering and physical sciences with oncology to change how we understand and treat this complex disease.

• share
• favorite_border

The UC Davis Department of Obstetrics and Gynecology is recruiting potential participants for a clinical trial of an investigational hormone-free monthly intravaginal method of contraception.

• share
• favorite_border

In a groundbreaking advance that could revolutionize bladder cancer treatment, a novel combination of cretostimogene grenadenorepvec and pembrolizumab has shown remarkable efficacy in patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

• share
• favorite_border

Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. March is Colorectal Cancer Awareness Month, contact our media team to set up interviews.

• share
• favorite_border

Study finds that mesalamine, a common anti-inflammatory drug, can fight the fungus Candida albicans in the gut, potentially preventing the risk of invasive candidiasis in patients with blood cancers.

• share
• favorite_border

According to preliminary data from a multi-institution Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, intensity modulated proton therapy (IMPT) achieved similar clinical outcomes and offered significant patient benefits when compared to traditional intensity modulated radiation therapy (IMRT) as part of chemoradiation treatment for patients with oropharyngeal (head and neck) cancer.

• share
• favorite_border

Over the last two decades, strides in cancer prevention, earlier detection, and novel treatments have reduced overall cancer mortality; however, cancer health disparities (CHD) persist among demographically diverse and intersecting populations.

• share
• favorite_border

A novel immunotherapy approach developed by Ludwig Cancer Research scientists employs a two-pronged attack against solid tumors to boost the immune system’s ability to target and eliminate cancer cells.

• share
• favorite_border

Based on an analysis of data from a regional cancer center, Dana-Farber Cancer Institute researchers calculate that, nationwide, cancer care that utilizes telehealth and local care would generate 33.1% less greenhouse gas emissions than the traditional model of in-person care. Study published in JAMA Oncology.

• share
• favorite_border

Cancer health disparities are differences in cancer burden experienced by members of marginalized communities. As such, discrimination based on gender identity and/or sexual orientation contributes to cancer disparities today. While data about cancer among members of the LGBTQ+ community is somewhat limited, recent studies have found that members of this group may have an elevated rate of cancer diagnoses. Our experts share more.

• share
• favorite_border

Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lymphoma, breast cancer, and glioblastoma. These findings are among more than 80 studies presented at ASCO that are led by Dana-Farber-affiliated researchers.

• share
• favorite_border

Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Virogen Biotechnology Inc., a clinical-stage biotechnology company, announced a groundbreaking strategic partnership today. This collaboration aims to propel the development of Virogen's cutting-edge fusion protein, VG712 (Resimmune), addressing significant unmet needs in oncology and immunotherapy.

• share
• favorite_border

Researchers from The University of Texas MD Anderson Cancer Center presented positive clinical results from two studies today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

• share
• favorite_border

Secondary analyses of a phase 3 clinical trial have revealed that breast cancer patients who reported high levels of pain and stress were more likely than their study peers to experience worse invasive disease-free survival (iDFS) and worse overall survival (OS).

• share
• favorite_border

Data from a large prospective cohort study reveal that a polygenic risk score has the potential to predict survival outcomes in patients with breast cancer.

• share
• favorite_border

New research from Yale Cancer Center reveals first-of-its-kind data from a phase I study in patients with hormone receptor positive HER2-negative metastatic breast cancer. The results, which assess the safety and efficacy of a treatment known as PF-07248144, offer new hope for treating this aggressive type of breast cancer.

• share
• favorite_border

A new mouse study of heart failure with preserved ejection fraction (HFpEF) found sex differences at the cellular level. The findings could have implications for how HFpEF is treated in women compared to men.

• share
• favorite_border

Researchers from Fred Hutch Cancer Center have found that active surveillance for prostate cancer patients with a low risk of progression is an effective alternative to immediate surgery or radiation to manage the disease.

• share
• favorite_border

Four teams of Dana-Farber Cancer Institute investigators have found that people experience discrimination and bias in different ways and in more realms of cancer care than previously understood. The findings, in different studies, suggest that oncology professionals and the systems they work in have more work to do to adapt to the realities of increasing diversity and inclusion, not only in the patient population but also in the oncology workforce.